Drug
VS-6766
VS-6766 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Completed2
Active, not recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
active_not_recruiting125%
completed250%
recruiting125%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_1
VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT05608252
active_not_recruitingphase_1
Phase I Trial of Defactinib and VS-6766.
NCT03875820
completedphase_1
Phase I Trial of VS-6766 Alone and in Combination With Everolimus
NCT02407509
completedphase_1
Food Effect of VS-6766 in Healthy Adult Subjects
NCT05187169
Clinical Trials (4)
Showing 4 of 4 trials
NCT05608252Phase 1
VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT03875820Phase 1
Phase I Trial of Defactinib and VS-6766.
NCT02407509Phase 1
Phase I Trial of VS-6766 Alone and in Combination With Everolimus
NCT05187169Phase 1
Food Effect of VS-6766 in Healthy Adult Subjects
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4